Canada — Health Canada & United States — Food and Drug Administration
10 shared events · Importance 5 · Last updated Jun 11, 2026
Live sentiment trends, interaction importance charts, and action volume tracking available on the
NewsDesk Dashboard
Tech
Canada — Health Canada: Canada — Health Canada>>> has not yet received an application to license daraxonrasib in Canada>>>. Its role is to regulate and approve new drugs for use in the country, impacting the timeline for Canadian patient access.
United States — Food and Drug Administration: The United States — Food and Drug Administration is expediting the review of daraxonrasib and has allowed expanded access to the drug, indicating its critical role in bringing this new treatment to patients.
May 29, 2026 · 74 articles
Business
Canada — Health Canada: Diagnosis is pursuing regulatory clearance with Canada — Health Canada>>> for its CARA platform, a key milestone for market expansion in Canada.
United States — Food and Drug Administration: Diagnosis completed a pre-submission process with the United States — Food and Drug Administration>>> in 2025, establishing a pathway for future 510(k) clearance in the United States.
Jun 05, 2026 · 11 articles
Business
Canada — Health Canada: Canada — Health Canada's regulation of ibogaine under the Food and Drugs Act and its listing on the Prescription Drug List provides a favorable regulatory environment for Optimi Health's operations.
United States — Food and Drug Administration: The United States — Food and Drug Administration's accelerated review process for psychedelic therapies, including ibogaine, is a key factor driving market interest and potential for new treatments.
Jun 08, 2026 · 14 articles
Business
Canada — Health Canada: Canada — Health Canada is the regulatory body whose approval is required for Medexus Pharmaceuticals to begin commercializing Allogeneic umbilical cord-derived CD34- cells, non-expanded/dorocubicel in Canada.
United States — Food and Drug Administration: The United States — Food and Drug Administration has granted orphan drug designation and regenerative medicine advanced therapy (RMAT) designations to Allogeneic umbilical cord-derived CD34- cells, non-expanded/dorocubicel.
Jun 10, 2026 · 6 articles
Tech
Canada — Health Canada: Canada — Health Canada previously approved REDEMPLO (plozasiran), contributing to its international market presence.
United States — Food and Drug Administration: The United States — Food and Drug Administration previously approved REDEMPLO (plozasiran) and granted it Breakthrough Therapy designation for severe hypertriglyceridemia, indicating its regulatory significance.
May 26, 2026 · 6 articles
Regulatory
Canada — Health Canada: Canada — Health Canada is the regulatory body in Canada to which Diagnosis plans to submit CARA for approval, impacting its commercialization in Canada.
Apr 08, 2026 · 6 articles
Business
Canada — Health Canada: Canada — Health Canada had licensed MyndTec's MyndMove system, indicating its prior regulatory approval.
Apr 08, 2026 · 6 articles
NEWSDESK
Explore this relationship live
Track how Canada — Health Canada and United States — Food and Drug Administration interact across events, view sentiment trends, and discover connected entities.
Open Dashboard